The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
Open accessAbstract
BACKGROUND: mutations occur in approximately 40% of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The PI3Kα-specific inhibitor alpelisib has shown antitumor activity in early studies. METHODS: -mutated cancer. Secondary end points included overall response and safety. RESULTS: -mutated cancer was greater with alpelisib-fulvestrant than with placebo-fulvestrant (26.6% vs. 12.8%); among patients with measurable disease in this cohort, the percentages were 35.7% and 16.2%, respectively. In the overall population, the most frequent adverse events of grade 3 or 4 were hyperglycemia (36.6% in the alpelisib-fulvestrant group vs. 0.7% in the placebo-fulvestrant group) and rash (9.9% vs. 0.3%). Diarrhea of grade 3 occurred in 6.7% of patients in the alpelisib-fulvestrant group, as compared with 0.3% of those in the placebo-fulvestrant group; no diarrhea of grade 4 was reported. The percentages of patients who discontinued alpelisib and placebo owing to adverse events were 25.0% and 4.2%, respectively. CONCLUSIONS: -mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. (Funded by Novartis Pharmaceuticals; SOLAR-1 ClinicalTrials.gov number, NCT02437318.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Only 20 patients (6%) in SOLAR-1 had been previously exposed to a CDK4/6 inhibitor.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the use of which as a single-agent is now suboptimal in the second line”
From Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. (2024) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hyperglycemia occurs early during therapy (median time of onset of about 2 weeks from initiation of alpelisib) with an incidence of $60% overall and typically resolves upon treatment cessation (220-222).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [220]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the PIK3CA-mutated cohort, alpelisib provided a PFS benefit of 11.0 months versus 5.7 months [hazard ratio (HR) for progression or death: 0.65; 95% confidence interval (CI) 0.50-0.85, P < 0.001].”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“Toxicity was substantially increased in the alpelisib arm, especially hyperglycaemia, rash, gastrointestinal (GI) complaints (nausea, vomiting, loss of appetite, mucositis, diarrhoea) and fatigue, which lead to dose reductions/interruptions in around 70% of patients and discontinuations in 25%.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J. C. S., Bhattacharyya, G. S., Biganzoli, L., Cardoso, M. J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,046
Self-citationUS Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Howlader, N., Altekruse, S. F., Li, C. I., Chen, V. W., Clarke, C. A., Ries, L. A. G., & Cronin, K. A. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju055 · Cited by 1,572
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Lopez, B. A., Barrios, C. H., Bergh, J. C. S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,194
Self-citationO’Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., André, F., Loibl, S., Loi, S., García-Murillas, I., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0264 · Cited by 657
Self-citationRugo, H. S., Rumble, R. B., Macrae, E. R., Barton, D. L., Connolly, H. K., Dickler, M. N., Fallowfield, L. J., Fowble, B. F., Ingle, J. N., Jahanzeb, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1487 · Cited by 640
Self-citationConvergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
Self-citationMiller, T. W., Hennessy, B. T., Gonzalez-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., Garcı́a-Echeverrı́a, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 555
Baselga, J. M., Im, S., Iwata, H., Cortés, J., Laurentiis, M. D., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M. J., Ito, Y., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30376-5 · Cited by 538
Self-citationFritsch, C. M., Huang, A., Chatenay‐Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D. A., Erdmann, D., Pover, A. D., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0865 · Cited by 504
Flagged first, then by citations
1 of the 25 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Juric D, Janku F, Rodón J, et al. Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: a phase 1b clinical trial. JAMA Oncol 2018 December 13 (Epub ahead of print).30543347
- Juric D Ciruelos E Rubovszky G et al. Alpelisib + fulvestrant for advanced breast cancer: subgroup analyses from the phase III SOLAR-1 trial. Presented at the San Antonio Breast Cancer Symposium San Antonio TX December 4–8 2018. abstract.
Cited by
Sorted by citations
Items 501–600 of 1,004
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
Chandrasekaran, S., Funk, C. R., Kleber, T. J., Paulos, C. M., Shanmugam, M., & Waller, E. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.718621 · Cited by 36
Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease
Page, K., Martinson, L. J., Fernández-García, D., Hills, A., Gleason, K. L. T., Gray, M. C., Rushton, A. J., Nteliopoulos, G., Hastings, R. K., Goddard, K. S., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00522 · Cited by 35
Molecular Pathology of Gastric Cancer
Kim, M., & Seo, A. N. (2022) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2022.22.e35 · Cited by 38
Luboff, A. J., & DeRemer, D. L. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241241531 · Cited by 35
Chopra, S. S., Jenney, A., Palmer, A. C., Niepel, M., Chung, M., Mills, C. E., Sivakumaren, S. C., Liu, Q., Chen, J.-Y., Yapp, C., et al. (2019) · Cell Systems · doi:10.1016/j.cels.2019.11.001 · Cited by 33
Targeting Protein Synthesis in Colorectal Cancer
Schmidt, S., Denk, S., & Wiegering, A. (2020) · Cancers · doi:10.3390/cancers12051298 · Cited by 36
The impact of COVID-19 on and recommendations for breast cancer care: the Singapore experience
Chan, J. J., Sim, Y., Ow, S. G. W., Lim, J. S. J., Kusumawidjaja, G., Zhuang, Q., Wong, R. X., Wong, F. Y., Tan, V. K. M., & Tan, T. J. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0157 · Cited by 34
PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer
Zhu, H., Du, C., Yuan, M., Fu, P., He, Q., Yang, B., & Cao, J. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.006 · Cited by 36
Jhaveri, K. L., Drago, J. Z., Shah, P. D., Wang, R., Pareja, F. G., Ratzon, F., Iasonos, A. E., Patil, S. N., Rosen, N. X., Fornier, M. N., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0047 · Cited by 34
Molecular Testing in Breast Cancer
Sun, L., Wu, A. S.-H., Bean, G. R., Hagemann, I. S., & Lin, C. (2021) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.07.026 · Cited by 37
Updates in endocrine therapy for metastatic breast cancer
Manohar, P. M., & Davidson, N. E. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0255 · Cited by 34
Haggstrom, L., Vardy, J. L., Carson, E., Segara, D., Lim, E., & Kiely, B. E. (2022) · Cancers · doi:10.3390/cancers14040920 · Cited by 44
Thill, M., Friedrich, M., Kolberg‐Liedtke, C., Albert, U., Banys‐Paluchowski, M., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., Fallenberg, E. M., et al. (2021) · Breast Care · doi:10.1159/000516420 · Cited by 34
Self-citationNuclear translocation of p85β promotes tumorigenesis of PIK3CA helical domain mutant cancer
Hao, Y., He, B., Wu, L., Li, Y., Wang, C., Wang, T., Sun, L., Zhang, Y., Zhan, Y., Zhao, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29585-x · Cited by 34
Meegdes, M., Geurts, S. M. E., Erdkamp, F., Dercksen, M. W., Vriens, B. E. P. J., Aaldering, K. N. A., Pepels, M. J. A. E., van de Winkel, L., Peters, N. A. J. B., Tol, J., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100573 · Cited by 36
Masri, J. E., & Phadke, S. D. (2022) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000721 · Cited by 35
de Oliveira, K. A., Sengupta, S., Yadav, A. K., & Clarke, R. C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1083048 · Cited by 32
Thill, M., Kolberg‐Liedtke, C., Albert, U., Banys-Paluchowski, M. J., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., Ditsch, N., Fallenberg, E. M., et al. (2023) · Breast Care · doi:10.1159/000531579 · Cited by 34
Self-citationBreast Cancer Circulating Tumor Cells: Current Clinical Applications and Future Prospects
Cani, A. K., & Hayes, D. F. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvad191 · Cited by 34
Howard, F. M., Hieromnimon, H. M., Ramesh, S., Dolezal, J. M., Kochanny, S. E., Zhang, Q., Feiger, B., Peterson, J., Fan, C., Perou, C. M., et al. (2024) · Science Advances · doi:10.1126/sciadv.adq0856 · Cited by 33
The potential of ctDNA analysis in breast cancer
Tzanikou, E., & Lianidou, E. S. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1670615 · Cited by 33
Sharifi, M. N., Anandan, A., Grogan, P. T., & O'Regan, R. M. (2020) · Cancer · doi:10.1002/cncr.32931 · Cited by 36
Kharenko, O. A., Patel, R. G., Calosing, C., & van der Horst, E. H. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00375-9 · Cited by 34
Gambardella, V., Lombardi, P., Carbonell‐Asins, J. A., Tarazona, N., Cejalvo, J. M., González‐Barrallo, I., Martín-Arana, J., Tébar-Martínez, R., Viala, A., Bruixola, G., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01502-x · Cited by 33
Sethakorn, N., Héninger, E., Sánchez‐de‐Diego, C., Ding, A. B., Yada, R. C., Kerr, S. C., Kosoff, D., Beebe, D. J., & Lang, J. M. (2022) · Cancers · doi:10.3390/cancers14030757 · Cited by 33
Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue
Loria, R., Vici, P., Lisa, F. S. D., Soddu, S., Maugeri‐Saccà, M., & Bon, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877380 · Cited by 34
Voutsadakis, I. A., & Stravodimou, A. (2023) · Anticancer Research · doi:10.21873/anticanres.16241 · Cited by 37
Bertho, M., Fraisse, J., Patsouris, A., Cottu, P. H., Arnedos, M., Pérol, D., Jaffré, A., Gonçalvès, A., Lebitasy, M.-P., D’Hondt, V., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920987657 · Cited by 32
Clinical and Biological Aspects of Disseminated Tumor Cells and Dormancy in Breast Cancer
Ring, A., Spataro, M., WICKI, A. N., & Aceto, N. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.929893 · Cited by 34
Chung, W., Huang, W.-L., Lee, C., Hsu, H., Huang, W., Liu, Y., & Su, W. (2022) · PubMed Central · Cited by 32
PIK3CA mutations in endocrine-resistant breast cancer
Schagerholm, C., Robertson, S., Toosi, H., Sifakis, E. G., & Hartman, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-62664-1 · Cited by 32
Targeted therapy for capillary-venous malformations
Zerbib, L., Ladraa, S., Fraissenon, A., Bayard, C., Firpion, M., Venot, Q., Protic, S., Hoguin, C., Thomas, A., Fraitag, S., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01862-9 · Cited by 32
Javed, S. R., Skolariki, A., Zameer, M. Z., & Lord, S. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02833-1 · Cited by 38
de Beça, F. F., Krings, G., Chen, Y., Hosfield, E. M., Vohra, P., Sibley, R. K., Troxell, M. L., West, R. B., Allison, K. H., & Bean, G. R. (2020) · Modern Pathology · doi:10.1038/s41379-020-0511-6 · Cited by 35
Genomics-guided pre-clinical development of cancer therapies
Francies, H. E., McDermott, U., & Garnett, M. J. (2020) · Nature Cancer · doi:10.1038/s43018-020-0067-x · Cited by 32
Breast Cancer in Patients 80 Years-Old and Older
Bertolo, A. J., Rosso, C., & Voutsadakis, I. A. (2020) · European Journal of Breast Health · doi:10.5152/ejbh.2020.5659 · Cited by 34
Mao, N., Zhang, Z., Lee, Y. S., Choi, D., Rivera, A. C. A., Li, D., Lee, C., Haywood, S., Chen, X., Chang, Q., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25341-9 · Cited by 33
Corné, J., Du, F. L., Quillien, V., Godey, F., Robert, L., Bourien, H., Brunot, A., Crouzet, L., Perrin, C., Lefeuvre‐Plesse, C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-96644-6 · Cited by 32
Radwan, I. T., Elwahy, A. H. M., Darweesh, A. F., Sharaky, M. M., Bagato, N. M. A., Khater, H. F., & Salem, M. E. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133454 · Cited by 32
Recent advances of tanshinone in regulating autophagy for medicinal research
Wu, S., Zhao, K., Wang, J., Liu, N., Nie, K., Qi, L., & Xia, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1059360 · Cited by 32
Keam, B., Hong, M. H., Shin, S. H., Heo, S. G., Kim, J. E., Ahn, H. K., Lee, Y., Park, K. U., Yun, T., Lee, K., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02786 · Cited by 32
A Review of the Advancements in Targeted Therapies for Breast Cancer
Jallah, J. K., Dweh, T. J., Anjankar, A. P., & Palma, O. (2023) · Cureus · doi:10.7759/cureus.47847 · Cited by 35
Li, X., Chen, G., Wang, F., Guo, X., Zhang, R., Liu, P., Dong, L., Yu, W., Wang, H., Wang, H., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1483 · Cited by 33
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer
Bielo, L. B., Trapani, D., Nicolò, E., Valenza, C., Guidi, L., Belli, C., Kotteas, E. A., Marra, A., Prat, A., Fusco, N., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102761 · Cited by 36
Liquid biopsy in triple-negative breast cancer: unlocking the potential of precision oncology
Mazzeo, R., Sears, J., Palmero, L., Bolzonello, S., Davis, A. A., Gerratana, L., & Puglisi, F. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103700 · Cited by 34
An evaluation of fulvestrant for the treatment of metastatic breast cancer
Soleja, M., Raj, G. V., & Unni, N. G. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1651293 · Cited by 29
Hyman, D. M., Tran, B., Paz-Ares, L. G., Machiels, J.-P., Schellens, J. H. M., Bedard, P. L., Campone, M., Cassier, P. A., Sarantopoulos, J., Vaishampayan, U. N., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00221 · Cited by 31
Self-citationManagement of ER positive metastatic breast cancer
McAndrew, N. P., & Finn, R. S. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.07.005 · Cited by 33
Bujak, A. Z., Weng, C.-F., Silva, M. J., Yeung, M. M., Lo, L. L., Ftouni, S., Litchfield, C., Ko, Y.-A., Kuykhoven, K. S., van Geelen, C. T., et al. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003363 · Cited by 33
Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?
Clark, A. S., Makhlin, I., & DeMichele, A. M. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3624 · Cited by 30
The Epigenetic landscape of Circulating tumour cells
Vasantharajan, S. S., Eccles, M. R., Rodger, E. J., Pattison, S. T., McCall, J. L., Gray, E. S., Calapre, L., & Chatterjee, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188514 · Cited by 30
Meng, X.-Y., Zhang, H., Ren, Y., Wang, K., Chen, J., Su, R., Jiang, J., Wang, P., & Ma, Q. (2021) · PubMed Central · Cited by 31
Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases
Huang, R. S. P., Haberberger, J., McGregor, K., Mata, D. A., Decker, B. J., Hiemenz, M., Lechpammer, M., Danziger, N. A., Schiavone, K., Creeden, J., et al. (2021) · The Oncologist · doi:10.1002/onco.13855 · Cited by 32
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer
Koshkin, V. S., Patel, V. G., Ali, A., Bilen, M. A., Ravindranathan, D., Park, J. J., Kellezi, O., Cieslik, M. P., Shaya, J. A., Cabal, A., et al. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00433-1 · Cited by 30
Madsen, R. R., Erickson, E. C., Rueda, O. M., Robin, X., Caldas, C., Toker, A., Semple, R. K., & Vanhaesebroeck, B. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009876 · Cited by 33
Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic
Skolariki, A., D’Costa, J., Little, M., & Lord, S. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00078 · Cited by 34
Gennari, A., Brain, E. G. C., Censi, A. D., Nanni, O., Wuerstlein, R., Frassoldati, A., Cortés, J., Rossi, V., Palleschi, M., Alberini, J. L., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.02.007 · Cited by 30
Zou, Q., Liao, K., Li, G., Huang, X., Zheng, Y., Yang, G., Luo, M., Xue, E. Y., Lan, C., Wang, S., et al. (2024) · Advanced Materials · doi:10.1002/adma.202407425 · Cited by 30
Rugo, H. S., Oliveira, M., Howell, S. J., Dalenc, F., Cortés, J., Gómez, H., Hu, X., Jhaveri, K. L., Криворотько, П. В., Loibl, S., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103697 · Cited by 34
Self-citationMalik, S., & Zaheer, S. (2025) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2025.100299 · Cited by 34
The Future of ER+/HER2− Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors
Stravodimou, A., & Voutsadakis, I. A. (2020) · Anticancer Research · doi:10.21873/anticanres.14486 · Cited by 30
Takayanagi, D., Hirose, S., Kuno, I., Asami, Y., Murakami, N., Matsuda, M., Shimada, Y., Sunami, K., Komatsu, M., Hamamoto, R., et al. (2021) · Cancers · doi:10.3390/cancers13061215 · Cited by 29
Cao, J., Wu, D., Wu, G. J., Wang, Y., Ren, T., Wang, Y., Lv, Y., Sun, W., Wang, J., Qian, C., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03904-4 · Cited by 30
ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins
Alcon, C., Zañudo, J. G. T., Albert, R., Wagle, N., Scaltriti, M., Letai, A. G., Samitier, J., & Montero, J. (2021) · Cells · doi:10.3390/cells10071659 · Cited by 32
Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies
Sakach, E. A., O'Regan, R. M., Meisel, J. L., & Li, X. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.09.003 · Cited by 33
A multidisciplinary approach to optimizing care of patients treated with alpelisib
Rugo, H. S., Lacouture, M. E., Goncalves, M. D., Masharani, U. B., Aapro, M., & O’Shaughnessy, J. (2021) · The Breast · doi:10.1016/j.breast.2021.12.016 · Cited by 31
Self-citationCanine models of human cancer: Bridging the gap to improve precision medicine
Nance, R. L., Sajib, A. M., & Smith, B. F. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.12.003 · Cited by 29
Martín-Romano, P., Mezquita, L., Hollebecque, A., Lacroix, L., Rouleau, É., Gazzah, A., Bahleda, R., Planchard, D., Varga, A., Baldini, C., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00484 · Cited by 32
Self-citationPIK3CA-Related Disorders: From Disease Mechanism to Evidence-Based Treatments
Morin, G., Zerbib, L., Kaltenbach, S., Fraissenon, A., Balducci, E., Asnafi, V., & Canaud, G. (2024) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-121222-114518 · Cited by 30
Integrative multi-omics characterization reveals sex differences in glioblastoma
Jang, B., Yoon, D., Lee, J. Y., Kim, J., Hong, J., Koo, H., & Sa, J. K. (2024) · Biology of Sex Differences · doi:10.1186/s13293-024-00601-7 · Cited by 29
Ferro, A., Campora, M., Caldara, A., Lisi, D. D., Lorenzi, M., Monteverdi, S., Mihai, R., Bisio, A., Dipasquale, M., Caffo, O., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123611 · Cited by 31
Girigoswami, K., & Girigoswami, A. (2025) · Medical Sciences · doi:10.3390/medsci13040275 · Cited by 31
Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer
Lee, M. J., Jin, N., Grandis, J. R., & Johnson, D. E. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118679 · Cited by 29
Yokose, T., Kitago, M., Matsuda, S., Sasaki, Y., Masugi, Y., Nakamura, Y., Shinoda, M., Yagi, H., Abe, Y., Oshima, G., et al. (2020) · Cancer Science · doi:10.1111/cas.14425 · Cited by 28
van de Stolpe, A., Verhaegh, W., Blay, J., Ma, C. X., Pauwels, P., Pegram, M. D., Prenen, H., Ruysscher, D. D., Saba, N. F., Slovin, S. F., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2020.598118 · Cited by 29
Guercio, B. J., Iyer, G., Kidwai, W. Z., Lacouture, M. E., Ghafoor, S., Rossi, A. M., Assis, D. N., Chen, Y., BUSAM, K. J., Janjigian, Y. Y., et al. (2021) · Case Reports in Oncology · doi:10.1159/000514345 · Cited by 29
Lee, J. B., Jung, M., Beom, S., Kim, G. M., Kim, H. R., Choi, H. J., Sohn, J., Ahn, J. B., Rha, S. Y., & Chung, H. C. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01085-7 · Cited by 31
The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer
Davidson, B. A., Croessmann, S., & Park, B. H. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01422-w · Cited by 29
Fallah, Y., Demas, D. M., Lu, J., He, W., & Shajahan‐Haq, A. N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.681530 · Cited by 29
Kishikawa, T., Higuchi, H., Wang, L., Panch, N., Maymi, V., Best, S., Lee, S., Notoya, G., Toker, A., Matesic, L. E., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140436 · Cited by 32
Shen, S., Chen, Y., Carpio, A., Chang, C., & Iyengar, N. M. (2023) · Cancer · doi:10.1002/cncr.34928 · Cited by 38
Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers
Shan, K. S., Bonano-Rios, A. M., Theik, N. W. Y., Hussein, A. M., & Blaya, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041973 · Cited by 31
Applications of Liquid Biopsy for Surgical Patients With Cancer
Mahuron, K. M., & Fong, Y. (2023) · JAMA Surgery · doi:10.1001/jamasurg.2023.5394 · Cited by 31
López‐Cortés, A., Cabrera‐Andrade, A., Echeverría‐Garcés, G., Echeverría-Espinoza, P., Pineda-Albán, M., Elsitdie, N., Bueno‐Miño, J., Segundo, C. M. C., Dorado, J., Pazos, A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-68565-7 · Cited by 28
Sammons, S. L., Shastry, M., Dent, S. F., Anders, C. K., & Hamilton, E. P. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.06.017 · Cited by 28
Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development
Pal, A., Shinde, R., Miralles, M. S., Workman, P., & Bono, J. S. D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00489-x · Cited by 28
Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer
Tsimberidou, A. M., Shaw, J. V., Juric, D., Verschraegen, C. F., Weise, A. M., Sarantopoulos, J., Junior, G. L. L., Nemunaitis, J. J., Mita, M. M., Park, H., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01132-z · Cited by 32
Self-citationAlpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma
Xu, H., Chen, K., Shang, R., Chen, X., Zhang, Y., Song, X., Evert, M., Zhong, S., Li, B., Calvisi, D. F., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04206-5 · Cited by 33
García-Sáenz, J. Á., Martínez-Jáñez, N., Cubedo, R., Jerez, Y., Lahuerta, A., González-Santiago, S., Ferrer, N., Ramos, M., Alonso-Romero, J. L., Antón, A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2652 · Cited by 28
Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
Nepote, A., Avallone, G., Ribero, S., Cavallo, F., Roccuzzo, G., Mastorino, L., Conforti, C., Paruzzo, L., Poletto, S., Schianca, F. C., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030828 · Cited by 28
Alpelisib to treat CLOVES syndrome, a member of the PIK3CA‐related overgrowth syndrome spectrum
Fontelles, G. G., Pastor, J. P., & Grande‐Moreillo, C. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15270 · Cited by 28
Fidalgo, J. A. P., Criscitiello, C., Carrasco, E., Regan, M. M., Leo, A. D., Ribi, K., Adam, V. S., & Bedard, P. L. (2022) · Future Oncology · doi:10.2217/fon-2022-0045 · Cited by 28
Tsuji, J., Li, T., Grinshpun, A., Coorens, T. H. H., Russo, D., Anderson, L., Rees, R., Nardone, A., Patterson, C., Lennon, N. J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2305 · Cited by 28
DNMT3a-dermatopontin axis suppresses breast cancer malignancy via inactivating YAP
Ye, D., Wang, Y., Deng, X., Zhou, X., Liu, D., Zhou, B., Zheng, W., Wang, X., & Fang, L. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05657-8 · Cited by 28
Nabieva, N., & Fasching, P. A. (2023) · Cancers · doi:10.3390/cancers15061763 · Cited by 29
Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies
Leong, D. P., Cirne, F., Aghel, N., Vila, R. C. B., Cavalli, G. D., Ellis, P. M., Healey, J. S., Whitlock, R. P., Khalaf, D., Mian, H. S., et al. (2023) · JACC CardioOncology · doi:10.1016/j.jaccao.2023.05.008 · Cited by 30
Li, S., Chen, J., Zhang, M., Zhang, W., Zhang, W.-Y., & Ma, C. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116425 · Cited by 27
Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies
Hancock, G. R., Gertz, J., Jeselsohn, R. M., & Fanning, S. W. (2024) · Endocrinology · doi:10.1210/endocr/bqae051 · Cited by 28
Clinical application of whole-genome sequencing of solid tumors for precision oncology
Kim, R., Kim, S., Oh, B. B.-L., Yu, W. S., Kim, C. W., Hur, H., Son, S., Yang, M. J., Cho, D. S., Ha, T., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01288-x · Cited by 28
Liu, L., Graff, S. L., & Wang, Y. (2024) · Cancers · doi:10.3390/cancers17010016 · Cited by 29
Metadata
- Authors
- André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., Yamashita, T., Lu, Y.-S., Inoue, K., Takahashi, M., Pápai, Z., Longin, A.-S., Mills, D., Wilke, C., Hirawat, S., & Juric, D.
- Affiliations
- Université Paris-Sud (FR)
- From Institut Gustave Roussy, INSERM Unité 981, Université Paris-Sud, Villejuif (F.A.), Institut de Cancérologie de l’Ouest, St. Herblain (M.C.), and Novartis Pharma, Paris (A.-S.L.) — all in France; Hospital Universitario 12 de Octubre, Madrid (E.C.); National Institute of Oncology (G.R.) and Duna Medical Center (Z.P.), Budapest, Hungary; German Breast Group, Neu-Isenburg, and Center for Hematology and Oncology Bethanien, Frankfurt — both in Germany (S.L.); UCSF Helen Diller Family Comprehensive...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-05-16
- Volume
- 380
- Issue
- 20
- Pages
- 1929-1940
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2945564879
- Cited by
- 2,622
- References
- 25
- Citations by year
- 2026: 314 · 2025: 356 · 2024: 370 · 2023: 329 · 2022: 375 · 2021: 450 · 2020: 345 · 2019: 81
- FWCI
- 231.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Hispana (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- Funders
- Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- alpelisib, PIK3CA mutation, hormone receptor-positive breast cancer, HER2-negative breast cancer, advanced breast cancer, PI3Kα inhibitor, fulvestrant, endocrine therapy, hyperglycemia, diarrhea, adverse events
- MeSH terms
- Fulvestrant, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Diarrhea, Female, Humans, Middle Aged, Mutation, Receptors, Estrogen, Receptors, Progesterone, Thiazoles, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Agents, Hormonal, Class I Phosphatidylinositol 3-Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
